Key points are not available for this paper at this time.
How the “tides” have turned in pharma manufacturing Two seasoned experts from CPI, Medicines Manufacturing Innovation Centre, detail how the “tides” have turned in pharma manufacturing. Oligonucleotides and peptides are two of the fastest-growing pharmaceutical drug modalities with the potential to revolutionise the treatment of many human diseases. The incredible demand for new type II diabetes and obesity peptide therapies recently launched by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) and the acceleration in approvals of oligonucleotide therapies make them a hot topic in the pharmaceutical world.
McElhone et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: